Kyverna Therapeutics (NASDAQ:KYTX) Stock Rating Lowered by Wall Street Zen

Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

KYTX has been the topic of several other reports. HC Wainwright upped their price target on Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Wells Fargo & Company upped their target price on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Finally, Morgan Stanley set a $33.00 price objective on shares of Kyverna Therapeutics in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $28.67.

Kyverna Therapeutics Price Performance

KYTX stock opened at $7.26 on Friday. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $13.67. The company has a market cap of $317.99 million, a P/E ratio of -1.95 and a beta of 3.45. The firm has a 50-day moving average of $8.53 and a 200 day moving average of $6.65.

Insider Activity at Kyverna Therapeutics

In other Kyverna Therapeutics news, Director Beth C. Seidenberg acquired 133,333 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were acquired at an average cost of $7.50 per share, with a total value of $999,997.50. Following the transaction, the director owned 869,317 shares of the company’s stock, valued at $6,519,877.50. The trade was a 18.12% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CTO Karen Marie Walker sold 23,998 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the sale, the chief technology officer owned 22,636 shares in the company, valued at approximately $276,159.20. This represents a 51.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

Institutional Investors Weigh In On Kyverna Therapeutics

Institutional investors have recently modified their holdings of the business. AIGH Capital Management LLC purchased a new position in Kyverna Therapeutics in the 4th quarter worth about $14,100,000. Propel Bio Management LLC bought a new stake in shares of Kyverna Therapeutics in the fourth quarter worth approximately $6,267,000. Alyeska Investment Group L.P. bought a new stake in shares of Kyverna Therapeutics in the fourth quarter worth approximately $5,640,000. RFG Advisory LLC purchased a new position in shares of Kyverna Therapeutics during the fourth quarter valued at approximately $4,185,000. Finally, Woodline Partners LP bought a new position in Kyverna Therapeutics during the third quarter valued at approximately $1,513,000. 18.08% of the stock is owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.